Search Results - "Arredouani, M. Simo"

Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4 by Sowalsky, Adam G, Kissick, Haydn T, Gerrin, Sean J, Schaefer, Rachel J, Xia, Zheng, Russo, Joshua W, Arredouani, M Simo, Bubley, Glenn J, Sanda, Martin G, Li, Wei, Ye, Huihui, Balk, Steven P

“…The molecular features that account for the distinct histology and aggressive biological behavior of Gleason pattern 4 (Gp4) versus Gp3 prostate cancer, and…”
Get full text

Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model by Varghese, Bindu, Lynch, Lydia, Vriend, Lianne E., Draganov, Dobrin, Clark, Justice M., Kissick, Haydn T., Varghese, Sharlin, Sanda, Martin G., Dranoff, Glenn, Arredouani, M. Simo, Balk, Steven P., Exley, Mark A.

“…Invariant natural killer T cells (iNKT cells) express a semi-invariant T cell receptor that recognizes certain glycolipids (including α-galactosylceramide,…”
Get full text

A Novel Strategy for Off-the-Shelf T Cell Therapy Which Evades Allogeneic T Cell and NK Cell Rejection by Zhang, Yong, Goel, Surbhi, Prodeus, Aaron, Jetley, Utsav, Tan, Yiyang, Averill, John, Ranade, Utkarsha, Balwani, Ishina, Dutta, Ivy, Sharma, Palak, Venkatesan, Priya, Liu, Dai, Roy, Matthew, O′Connell, Daniel, Arredouani, Simo M, Keenan, Marie, Lescarbeau, Reynald, Schultes, Birgit C

“…Introduction. Despite the success of autologous chimeric antigen receptor (CAR)-T cells, barriers to a more widespread use of this potentially curative therapy…”
Get full text

NTLA5001, a T Cell Product Candidate with CRISPR-Based Targeted Insertion of a High-Avidity, Natural, WT1-Specific TCR, Shows Efficacy in In Vivo Models of AML and ALL by Ruggiero, Eliana, Liu, Dai, Prodeus, Aaron, Becker, Amy M, Foisey, Maxwell, Balwani, Ishina, Dutta, Ivy, Zhang, Qingzhan, Arredouani, Simo M, McKee, Mark, Ciceri, Fabio, Sepp-Lorenzino, Laura, Bonini, Chiara, Schultes, Birgit C

“…Adoptive cell therapy using T cells expressing transgenic (tg) tumor antigen-targeting T cell receptors (TCRs) has become an attractive modality to treat…”
Get full text

Androgens modulate anti-tumor immunity through interference with the T lymphocyte differentiation program (P1169) by Arredouani, M. Simo, Kissick, Haydn, Dunn, Laura, Sanda, Martin

“…Abstract Androgen modulation of immunity to tumor antigens have implications on designing novel prostate cancer immunotherapy regimens. However, the mechanisms…”
Get full text

Distinct transcriptome of regulatory T cells in prostate cancer (162.18) by Arredouani, M. Simo, Kissick, Haydn, Dunn, Laura, Sanda, Martin

“…Abstract The inhibitory role of regulatory T-cells (Tregs) in cancer is now well established. Furthermore, inhibition of Treg function has been shown both…”
Get full text

Abstract A31: Human prostate cancer transcriptome reveals distinct signaling pathway dysregulations associated with TMPRSS2:ERG fusion by Bhasin, Manoj, Lu, Bin, Arredouani, M. Simo

“…Abstract Introduction: The gene rearrangement leading to the fusion of the TMPRSS2 and ERG genes on chromosome 21 occurs in about 50% of prostate cancer cases…”
Get full text

Immunogenic Peptides Derived from the Transcription Factor ERG as a Vaccine for Prostate Cancer (162.17) by Kissick, Haydn, Dunn, Laura, Lu, Bin, Sanda, Martin, Arredouani, M. Simo

“…Abstract The suitability of immunotherapy as a treatment for prostate cancer (PCa) has recently been demonstrated in a number of clinical trials. While these…”
Get full text

Breaking immune tolerance to prostate-associated tumor antigens through Tim-1 receptor (162.20) by Arredouani, M. Simo, Kissick, Haydn, Dunn, Laura, Strom, Terry, Sanda, Martin

“…Abstract It has been suggested that one factor limiting cancer immunotherapy in clinical trials are immunological checkpoints that impede vaccine-induced…”
Get full text

A novel iNKT-mediated vaccine maneuver overcomes PD-1-mediated T cell exhaustion in cancer (165.13) by Varghese, Bindu, Lynch, Lydia, Vriend, Lianne, Kissick, Haydn, Dunn, Laura, Varghese, Sharlin, Arredouani, M. Simo, Balk, Steven, Exley, Mark

“…Abstract Our immune system plays an important role in preventing cancer. However, tumor-derived immuno-suppression hinders effective anti-tumor immunity. T…”
Get full text

A novel iNKT cell-mediated vaccine maneuver induces potent long-lasting anti-tumor immunity for advanced prostate cancer by boosting CD8+T cell memory and function (53.24) by Varghese, Bindu, Lynch, Lydia, Vriend, Lianne, Kissick, Haydn, Dunn, Laura, Varghese, Sharlin, Dranoff, Glenn, Arredouani, M. Simo, Balk, Steven, Exley, Mark

“…Abstract iNKT cells have considerable therapeutic promise in cancer, but so far this has not been fully realized. At issue has been delivering iNKT ligand and…”
Get full text

Optimizing anti‐tumor immunity: Mechanisms and reversion of systemic iNKT defects in murine prostate cancer by Nowak, Michael, Ilyinski, Petr, Arredouani, M. Simo, Sanda, Martin, Balk, Stephen P, Exley, Mark A

“…Abstract only Breaking tolerance to self‐antigens represents a promising treatment approach, especially for cancers of noncritical organs. Invariant natural…”
Get full text

Exploiting the Good Guys: Th1 Antiviral & Antitumor Human & Mouse NKT Cells by Exley, Mark, Nowak, Michael, Yue, Simon, Scheuplein, Felix, Arredouani, M. Simo, Sanda, Martin, Sasada, Tetsuro, Balk, Steven

Get full text